Amgen's Repatha Results and Impact

Jim Cramer and Amgen CEO Bob Bradway review phase three Repatha heart-attack prevention data and implications for patient care.

Play episode from 14:41

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!